Portola, BMS, Pfizer Team Up to Test Their Drugs' Antidote
By Randy Osborne
Friday, November 2, 2012
Not every day do you see a company, in the course of developing its drug, sign a deal with two other firms that are working on a therapy in the same class. Even more unusual: The deal is designed to help come up with a reversing agent for both compounds, and others.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.